Why Elephants Don't Get Cancer: A Twenty-Copy Shield

Bölüm metni

A human body holds thirty trillion cells; an elephant carries a hundred times that, and lives about as long as we do. If every cell division is one more lottery ticket for cancer, elephants should have run out of luck long ago. Yet they die of cancer less often than we do — and we could only understand why once someone read their genome.

In nineteen seventy-seven, an epidemiologist working at Oxford was looking at cancer statistics and asked a question nobody was asking out loud. Richard Peto was at the time working on a model of how cancer arises; a simple and merciless model that still sits in the textbooks today. Cancer does not begin with a single accident. For a cell to slip out of control, several faults, several mutations, have to pile up in that same cell. One error that breaks the growth brake, another that disables the suicide mechanism, a third that cripples the system correcting copying errors. Each on its own is unlikely. But if your body holds a very large number of cells, and those cells keep on dividing for a very long time, low probability wins sooner or later.

Now take that model seriously and do the arithmetic. A human being has roughly thirty trillion cells. A mouse carries about a thousand times fewer cells than a human and lives on average two years; a human goes on up to eighty. Multiply the cell count by a thousand and the lifespan by thirty. If the risk of any given cell turning cancerous were the same from species to species, a human ought to see astronomically more cancer than a mouse. A difference so large that not one human would ever reach adulthood. But we do. That was what Peto noticed: the model is consistent on the inside, and it does not match the world outside.

Scale things up and it gets stranger still. Think of an African elephant. Four, five, sometimes six tonnes. It carries roughly a hundred times more cells than a human and lives sixty, seventy years in the wild. So it has a human's long life, with a hundred times a human's cells. Run the same arithmetic for the elephant and this is what falls out: no elephant should ever reach adolescence. It ought to be impossible for an old female to lead the herd to water on forty years of memory, because that female should long since have died with dozens of tumours. Move on to the blue whale, look at more than a hundred tonnes of mass and a lifespan beyond eighty years, and the arithmetic becomes outright absurd.

But elephants do not die of cancer. Not at our rate, at any rate. In two thousand fifteen a team led by Lisa Abegglen and Joshua Schiffman at the University of Utah decided to close the question with numbers. They went into zoo necropsy records. They combed through fourteen years of necropsy data from the San Diego Zoo, along with a separate database covering six hundred and forty-four elephant deaths. The result was this: about four point eight percent of elephants die of cancer. In humans the same figure runs between eleven and twenty-five percent, depending on which country and which year you look at. So the animal carrying a hundred times more cells is the animal whose chance of dying from cancer is a third of ours, or even a fifth.

This is called Peto's paradox, and calling it a paradox is a little unfair. There is no contradiction in nature. No law of physics breaks in the elephant. The contradiction is in our heads, or more precisely in our model. The model assumed that cancer risk per cell is constant from animal to animal. Nature never signed that assumption. And that is where the real force of Peto's question lies. It contains not an answer but a claim: if large animals are not getting as much cancer as they ought to, then evolution must have handed them something extra. A shield. And that shield, in principle at least, is a findable thing. It sits inside the genome; it can be read, it can be counted.

For thirty-eight years this stayed a thought experiment. Then somebody looked at the elephant's genome.

Where to look was, in fact, obvious. There is one gene in cancer biology that has been nicknamed the guardian of the genome: TP53. Its job, described plainly, is unnervingly simple. When DNA damage appears in a cell, the protein TP53 produces steps in, halts division, and calls in the repair crew. If the damage is too severe to be repaired, it presses a second button and tells the cell to kill itself. Eliminating a suspect cell instead of repairing it means cancelling the first step of cancer before that step is even taken.

In humans there is a single copy of this gene; one version from the mother, one from the father. There is a painful reason we know how critical that single copy is. There is an inherited condition called Li-Fraumeni syndrome, in which a person is born missing one of the working copies of TP53. They are left with one functioning version rather than two. The result is a lifetime cancer risk above ninety percent. The absence of a single version shifts a person's cancer statistics that far.

What the Utah team found in the elephant genome was this: twenty copies of TP53. Forty versions. Twenty times what we carry.

Finding it is one thing; showing that it works is another. The team took blood cells from elephants and exposed them to radiation in the laboratory. They did the same to healthy human cells and to cells from people with Li-Fraumeni syndrome. The moment the elephant cells registered the damage, they killed themselves at a far higher rate than the human cells did. The Li-Fraumeni cells were the most reluctant of all; they carried on living with the damage. What emerged looked like a spectrum. At one end a cell that ignores damage, in the middle ours, and at the far end the elephant cell, which has no tolerance for doubt whatsoever.

The elephant strategy is not to repair but to sacrifice. The reason it can afford that is entirely practical: the elephant has cells to spare. An attitude that would count as wastefulness at our scale becomes, at that mass, a sensible insurance policy.

During those same years, in Chicago, Vincent Lynch's team was coming at the problem from another direction, and found a stranger detail. Nineteen of the elephant's twenty copies are not ordinary gene copies. They are called retrogenes. They form when the processed, message-stage copy of a gene is pasted back into the DNA in reverse; they contain none of the intervening pieces called introns. In other words, the elephant's genome has photocopied the same document over and over and filed it in different folders.

Lynch's team went a step further and looked at the elephant's relatives. The rock hyrax and the manatee are small animals sitting on the same evolutionary branch as the elephant, and they have only a handful of these copies. The number of copies rises as the body grows along the family tree. This is a little more than correlation. As the bodies of the elephant's ancestors grew, so did the stock of spare versions protecting that body. When the team transferred the elephant retrogenes into mouse cells, the mouse cells too began killing themselves more readily in the face of damage. So the copies are not decorative; they work.

Then in two thousand eighteen, with a study published in the journal Cell Reports, came the most cinematic part of the story. Lynch's team found a large number of copies of a gene called LIF in the elephant genome; between seven and eleven of them. Almost all of them are pseudogenes, which is to say dead. Broken texts with the key snapped off, no longer read. Genomes are full of graveyards like this; we have them too.

But one of them, the copy named LIF6, has climbed out of the grave. Right at the head of that copy, a piece of DNA that shifted position millions of years ago has stuck on a switch. And the thing that turns the switch is precisely TP53. The circuit runs like this: DNA damage occurs in the cell, TP53 wakes up, TP53 goes and switches on LIF6, and the protein LIF6 produces travels to the cell's mitochondria and punches straight through them. Once mitochondria are punctured, there is no way back for the cell. The researchers called it a zombie gene, because that is exactly what it is. Dead once, then returned in a different job. The elephant took a piece of scrap left over from its ancestors and turned it into a murder weapon.

It should be added that this is not the only solution. Nature has solved the same problem in entirely different ways in other species. The naked mole rat weighs all of thirty-five grams and lives more than thirty years, which is extraordinary for a rodent that size. And cancer is almost never seen in it. As Vera Gorbunova and Andrei Seluanov at the University of Rochester showed in two thousand thirteen, this animal's secret is not in TP53 copies. It lies in a molecule called hyaluronan that fills the spaces between its tissues. The hyaluronan the mole rat produces is more than five times larger than ours. That oversized molecule makes the cells hypersensitive; the instant cells touch one another they stop dividing, which means they never permit the crowding a tumour needs. When the researchers silenced the gene that produces this molecule, the animal's cells became prone to cancer. In two thousand twenty-three the same team transferred that gene into mice; cancer went down in the mice and lifespan went up.

So there is no single formula. The elephant hoarded copies; the naked mole rat packed gel between its cells. Two separate lineages found two separate answers to the same bill.

Everything I have described so far took a serious shaking in two thousand twenty-five. And that shaking corrected the story rather than demolishing it.

In January of two thousand twenty-five, Zachary Compton and colleagues from a large number of institutions combined the widest body of data yet assembled into a single analysis: sixteen thousand and forty-nine necropsy records, from two hundred and ninety-two species, across ninety-nine animal-care institutions. The result ran against Peto's forty-year-old observation. As body mass rose, the rate at which tumours appeared rose with it. The increase was small, but it was there: when mass went up tenfold, tumour risk climbed by about two point one percent. The same data threw up another interesting link as well; species with long gestation periods had less cancer. When gestation went up tenfold, tumour risk fell by five point three percent.

A month later, in February of two thousand twenty-five, a team including George Butler, Joanna Baker and Chris Venditti published a study of two hundred and sixty-three species in the journal of the United States National Academy of Sciences, and the title did not beat about the bush: no evidence for Peto's paradox in terrestrial vertebrates. Among amphibians, birds, mammals and squamate reptiles, large species were getting more cancer than small ones.

Care is needed here, because these two studies are saying something more measured than most of the news coverage suggested. Yes, the relationship is not zero. But look at the size of the relationship. The naive calculation expects that when mass goes up tenfold, risk goes up roughly tenfold too. What was measured is two percent. So the curve is not flat, but it is very nearly flat. The paradox has not been solved; it has been cut down to size. Somebody still has to fill the enormous gap in between, and what fills that gap are mechanisms like the elephant's twenty copies and the naked mole rat's hyaluronan.

The second finding from Venditti's team sits exactly in that gap. Among birds and mammals, the lineages whose body size grew rapidly over evolutionary time were the lineages with the lower cancer rates. In other words, the faster an animal got big, the more tightly it was forced to clamp down on cell control. The elephant fits this picture perfectly. A fast-growing lineage that paid the bill at the till.

It is also only honest to say that the argument is not closed. In July of two thousand twenty-five, Antoine Dujon and his team reanalysed the same data sets with Bayesian methods and arrived at a more cautious conclusion: the evidence in hand is not enough either to confirm or to reject the paradox outright. The reasons are concrete. All of these records come from zoos, whereas these defence systems evolved in the wild. Some species have hundreds of necropsy records and others have three or four, which shifts the curve easily. And diseases with wildly different biology are being tipped into one bag under the heading of cancer. This is not science collapsing; it is science working. An observation corrects itself as the data grow.

So what does all of this tell us? Not a direct promise of a cure, and let us be clear about that. Nobody is going to add nineteen TP53 retrogenes to the human genome tomorrow; such an application is entirely speculative today, and nobody knows what a body carrying extra suicide buttons would look like. But we already hold one piece of evidence, tried at laboratory scale, that did work: when the naked mole rat's gene was transferred into mice, the mice really did get less cancer. That shows that at least some of the solutions evolution has found are transferable between species. On the elephant side, researchers are examining the elephant's p53 protein directly as a therapeutic candidate; that work is still at an early stage and is not something proven in the clinic.

What lasts is the change of perspective. For a long time cancer was regarded as an unavoidable tax; the price of living, of carrying cells, of ageing. The elephant's genome changes that. Cancer risk is not a fixed constant of nature; it is an adjustable parameter. Evolution has pulled that parameter down independently, again and again: in the elephant by multiplying copies, in the naked mole rat by changing tissue chemistry, in other lineages by routes we have not yet fully worked out. A blind process has solved the same problem dozens of times with whatever scrap was to hand, with a stretch of gene that happened to duplicate, with the resurrection of a dead copy.

If something can be solved over and over, then that something belongs to engineering, not to fate. What sits in the genomes of elephants is precisely this knowledge.

Nöron Science'de bugünkü bölümün sonuna geldik. Yeni bir hikâyede yeniden buluşmak üzere.